Non-fucosylated Anti-Human PD-L1 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ49] (CAT#: BioBet-049ZP) Datasheet

Whole Human Antibody
ADCC-enhanced Durvalumab is a non-fucosylated anti-PD-L1 therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-PD-L1 Durvalumab, a biobetter by reducing fucosylation of the Fc region of Durvalumab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Bladder cancer
Therapeutic antibody; biobetter
Not Available

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Full Name
CD274 molecule
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and nonhematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin Vlike and Clike domains. Interaction of this ligand with its receptor inhibits Tcell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic Tcell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.
Alternative Names
B7-H, B7H1, PDL1, PD-L1, PDCD1L1, PDCD1LG1
Gene ID
Cellular Localization
Plasma membrane, Endosome
Involvement in Disease
Diseases associated with CD274 include Testicular Lymphoma and Smoldering Myeloma.
Related Pathways
Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.
1.It plays a key role in inducing and maintaining immune tolerance to oneself (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, it regulates the activation threshold of t cells and limits the effector response of t cells (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through an unknown activation receptor, it is possible to stimulate a subset of T cells to mainly produce interleukin 10 (IL10) (PubMed: 10581077). 2. Tumors use the pdcd1 mediated inhibitory pathway to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits the effector function of cytotoxic T lymphocytes (CTLs) (similar). The blockade of the pdcd1 mediated pathway leads to the reversal of the exhausted T cell phenotype and the normalization of the anti-tumor response, which provides a theoretical basis for cancer immunotherapy (through similarity).
Post-translational modifications
1.Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. 2.Glycosylation at Asn35, Asn192, Asn200, and Asn219 3.Modification sites at PhosphoSitePlus
Trade name
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
CAS number
Antibody Isotype
Human IgG1
Antibody Clone
Durvalumab (trade name Imfinzi) is a human immunoglobulin G1κ (IgG1κ) monoclonal antibody and is known as a checkpoint inhibitor drug. It was developed by Medimmune / AstraZeneca and was approved by the FDA in May 2017 for immunotherapy of previously treated patients with locally advanced or metastatic cancer of the urinary system.
Urothelial carcinoma ureter metastatic
Locally advanced Urothelial Carcinoma

Durvalumab is a human immunoglobulin G1κ (IgG1k) monoclonal antibody that blocks the binding of PD-L1 to PD-1 and CD80. PD1 signaling pathway can physiologically limit the activity of T cells and generate autoimmune or inflammatory responses in the body, which is the mechanism by which tumor cells develop immune resistance. Durvalumab-mediated blocking of the PD1 pathway further enhances T cell activation, effector T cell proliferation, NK cell activity, and cytokine production, thereby minimizing local progression or the growth of metastatic solid tumors.

Urothelial carcinoma ureter metastatic
Locally advanced Urothelial Carcinoma

All products and services are for Research Use Only. Do Not use in humans.


Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *